Lupin has received an approval for Bepotastine Tablets from the Central Drugs Standard Control Organisation (CDSCO). The company shall commence promoting the product in India shortly.
Bepotastine is a new second generation antihistamine medicine to be introduced into the Indian Pharmaceutical Market (IPM) which could benefit millions of patients suffering from allergic symptoms. It is a rapid acting antihistamine that effectively controls day time and night time triggers of allergic symptoms. Bepotastine is approved by PMDA Japan and is actively marketed in Japan and other South East Asian countries. The current market for plain antihistamines is estimated to be around Rs 860 crore growing at 14%, as per IMS MAT Mar 2017.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
